Introduction: Methylphenidate (MP) is often recommended for symptom control in advanced cancer. Little is known about its side effects in frail adults. Objectives: To evaluate MP-associated symptoms or side effects (S/E). Methods: Data was collected from 2 published prospective cohort series and a phase 2 study of MP for symptom control in advanced cancer. All 3 reports had identical dosing schedules and symptom assessments. Initial MP doses were 10 mg/d (5 mg at 8 AM and at 12 noon) titrated up to a maximum of 30 mg/d. Depression, fatigue, and symptoms identified as possible MP S/E were evaluated for presence (prevalence) and for severity (using categorical scales) before MP (day 0) and on days 3, 5, and 7 thereafter. The categorical scale used was none, mild, moderate, and severe. Results: 62 patients were enrolled. Fifty completed 7 days of MP with a median age of 69 (range 30-90) years. Thirty-five received MP 10 mg/day. Most (96%) had improvement in depression and/or fatigue. Among the 62 patients, new symptom prevalence throughout the study was agitation (16%), insomnia (16%), dry mouth (15%), nausea (10%), tremors (6%), anorexia (5%), headache (3%), palpitations (2%), and vomiting (2%). Patients could have more than 1 symptom simultaneously. Seven (11%) withdrew due to MP S/E. Some symptoms present before MP showed significant improvement during MP therapy. Conclusions: (1) Treatment with MP (10-20 mg/d) in advanced cancer is well tolerated. (2) S/E symptoms with MP appeared to improve spontaneously despite continued MP therapy. (3) Depression and fatigue improved at doses lower than those recommended in other clinical conditions. (4) MP improved depression and fatigue, and some secondary symptoms associated with them. Methylphenidate (MP) appears safe when used in the treatment of depression and fatigue in advanced cancer.
Introduction
Methylphenidate (MP; Ritalin, Novartis, East Hanover, New Jersey) is a central nervous system (CNS) stimulant structurally related to amphetamine. It is a competitive blocker of dopamine transporters, and to a lesser extent, norepinephrine and serotonin transporters. Therapeutic levels enhance extracellular dopamine levels in basal ganglia, prefrontal cortex, as well as other sites. [1] [2] [3] Methylphenidate is a racemate with d-threo-MP as the active enantiomer. 1, 2 It is well absorbed from the gastrointestinal tract; food enhances absorption. As a rule, we prescribe divided doses before meals in the morning and at noon to avoid insomnia and hopefully avoid side effects from too rapid absorption. [4] [5] [6] Peak plasma concentrations occur 1 to 3 hours after administration and drug half-life is about 2 hours. 1 Methylphenidate has been used in clinical practice mainly for attention deficit hyperactivity disorder (ADHD) in children and narcolepsy in adults. Methylphenidate may relieve both depression and fatigue in patients with cancer. [3] [4] [5] [6] Importantly, symptoms are relieved quickly in this frail cancer population with apparently few side effects (S/E), and rarely any drug interactions. 1 However, the literature regarding MP safety in individuals without cancer may not be applicable in advanced cancer because most studies have involved otherwise-healthy children with ADHD. In addition, symptoms occurring due to cancer progression, and S/E associated with medications common in advanced diseases (such as opioids) may be similar to MP S/E and difficult to differentiate. We therefore evaluated possible MP S/E in advanced cancer by examining new symptoms that developed after the introduction of MP. We did this in pooled data from 2 case series, and 1 Phase 2 study to determine the safety of MP in advanced cancer patients.
Methods

Background
Symptoms that might be identified as MP S/E were identified by reviewing the literature and various standard pharmacologic texts. Possible MP S/E were collected from 2 previously published case series and a phase 2 trial. One case series involved 10 hospice patients treated for depression. 4 Another was a series of 11 with advanced cancer, treated for fatigue. 5 In the phase 2 study, 41 cancer patients with depression were enrolled. 6 All 3 reports used a similar advanced cancer patient population and identical dosing schedules and symptom assessments ( Figure 1 ); therefore, it was reasonable to pool the symptom data.
Symptoms of depression and fatigue and possible S/E symptoms attributable to MP use (agitation, anorexia, dizziness, dry mouth, headache, insomnia, nausea, palpitation, tremors, and vomiting) were evaluated using a standardized symptom checklist at baseline (day 0) before MP and on days 3, 5, and 7 thereafter, via telephone or bedside interview. Symptoms were assessed using a categorical scale (0 ¼ none, 1 ¼ mild, 2 ¼ moderate, and 3 ¼ severe, respectively).
Lack of response for either fatigue or depression, and the absence of dose limiting symptoms by day 3 and then day 5 were indications to titrate the MP dose. Methylphenidate was started at 10 mg/day (5 mg at 8 AM and at 12 noon) on day 1. The dose was increased from 5 mg to 10 mg to 15 mg twice a day as indicated. The maximum allowable total daily dose was 30 mg/day. If a response was noted, the same dose was continued. Treatment was discontinued after 1 week if no improvement in the primary target symptoms was seen at the maximum dose, or if significant new symptoms developed, which could reasonably be identified as MP S/E without relief of fatigue or depression. For this analysis, all who received at least 1 dose of MP were evaluable for new S/E symptoms, and those who completed 7 days were evaluable for efficacy.
Statistical Analysis
Continuous variables are summarized as the mean, standard deviation, median, and range. Categorical variables are summarized as frequency counts and percentages; percentages were rounded to the nearest whole number. To describe symptom severity, a numerical value of 0, 1, 2, and 3 were assigned to none, mild, moderate, and severe symptoms, respectively. The mean scores were computed for each symptom at each follow-up day, and the Mantel-Haenszel correlation statistic was used to determine change in mean scores of symptom severity over time. SAS statistical software was used to analyze the data (SAS Institute, Inc, Cary, North Carolina). A P value < .05 was considered significant.
Results
Sixty-two patients from 3 studies were evaluable. Seven (11%) were withdrawn from the studies due to distressing new symptoms. Agitation (n ¼ 2); agitation and insomnia (n ¼ 2); agitation, dry mouth, and insomnia (n ¼ 1); dysphoria (n ¼ 1); and nightmares (n ¼ 1) were the reasons for withdrawal. Another 3 were lost to follow-up, 1 had MP discontinued on hospital admission, and 1 refused to continue MP despite absence of S/E. Fifty completed 7 days of MP; demographic data is in Table 1 . Fortyeight (96%) had improvement in depression and/or fatigue. Thirty-five (70%) responded at the 10-mg/ day dose level. Most were maintained on 10 mg/day throughout the study period. On day 7, 35 were on 10 mg/d, one 15 mg/d, thirteen 20 mg/d, and one 30 mg/d. Of the 50 who finished 7 days of therapy, moderate new symptoms occurred in 10: dry mouth (5), insomnia (2), agitation (1), anorexia (1), and nausea (1) . None had severe symptoms. New symptoms developing after MP (N ¼ 62) included: agitation (16%), insomnia (16%), dry mouth (15%), nausea (10%), tremors (6%), anorexia (5%), headache (3%), palpitations (2%), and vomiting (2%). Some had more than 1 new symptom. The mean symptom severity for each evaluation day is in Table 2 . Statistically significant improvements in preexisting agitation, anorexia, and dizziness were observed, in addition to less depression and fatigue.
Discussion
In advanced cancer, MP has been used to treat depression, fatigue, opioid-induced sedation, hiccups, to potentiate opioid analgesia, and to improve cognitive function. [7] [8] [9] Methylphenidate seems to be well tolerated in advanced disease. Several authors have described the use of MP in patients with cancer. Discontinuation due to adverse events is not common, according to our literature search of published prospective studies of adult patients with cancer, and there were no differences in dropout rates in placebo-controlled trials ( Table 3) . [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Agitation, confusion, tachycardia, and other S/E were reported in these studies ( Table 3 ). The percentage of patients that discontinued MP due to potential S/E is similar to ours, and is consistently below 20%. In our analysis, any new symptoms that developed after MP were assumed to imply MP S/E. However, disease progression can cause symptoms similar to MP S/E, and this complicated toxicity assessment. Tolerance to MP S/E may develop with sustained exposure (similar to nitroglycerin for angina). 24 Continuous drug exposure with sustained release MP may lead to tachyphylaxis to S/E, which means that S/E maybe transient and missed if assessment is infrequent. 24 Currently, there is a new formulation of MP, an extended-release form (OROS-MP or Concerta; Alza Corp,Mountain View, California). This product has a rapid onset of action (1-2 hours) and long duration of efficacy (10-12 hours) in children with ADHD after a single administration in the morning. 24 Its benefit in this population equals that of normal-release formulations, but with greater compliance. Sustained release MP may or may not have the same benefits as normal release MP in advanced cancer and this should be subject for future study.
In this study, 7 (11%) out of 62 patients withdrew due to presumed MP adverse events (agitation, dysphoria, insomnia, and nightmares). These events can reasonably be attributable to MP S/E given its pharmacology and the nature of the symptoms. Intuitively debilitated patients should be at greatest risk of drug side effects. But only 10 had new symptoms rated as moderate (dry mouth, insomnia); and none experienced new severe symptoms. Insomnia was the commonest new symptom despite the dose schedule at 8 AM and 12 noon. Single dose MP at 8 AM rather than divided between 8 AM and 12 noon might reduce insomnia, though there is no data to support this.
Methylphenidate improved cognitive impairment and hypoactive delirium in advanced cancer without increased seizure frequency. 17, 21 In our analysis, improved agitation, anorexia, and dizziness (present before MP administration) were also observed. This was surprising; worse agitation and anorexia would have been anticipated based on the pharmacology of MP, and reports of MP in ADHD and narcolepsy. The improvement in those symptoms might be secondary to less agitated depression and/or improved fatigue. It is noteworthy that these symptoms were not routinely monitored before and after MP administration in most prior studies of MP in advanced cancer. In our studies, depression and fatigue improved in most patients at doses lower than recommended in other clinical conditions. Adult MP doses necessary to block 50% of dopamine transporters (required for response) are usually 0.25 mg/kg or 17.5 mg total daily dose. Therefore, most patients would be anticipated to require greater than 10 mg per day for response. 24 Our research supports the therapeutic benefit of MP at lower doses. Recently a placebo-controlled trial demonstrated improvement in fatigue a week after starting MP treatment. 14 This improvement was not superior to placebo when fatigue intensity was assessed using FACIT-F and ESAS scales, but superior when using a subjective improvement scale; 46% in the MP group reported moderate or severe benefit versus 27% in the placebo group; a significant difference. Perhaps the psychometric properties of fatigue assessment instruments should be revisited. Further controlled phase III trials are still needed.
Psychostimulants appear to be reasonably safe even in those with respiratory insufficiency. 25 Although most experience improvement in target symptoms, some will experience worsening symptoms compatible with S/E so it is important to monitor symptom profiles in those on MP. Multiple studies have shown a low risk for MP abuse though caution should be used in those with a history of addiction. 1 The S/E profile with chronic dosing, patient satisfaction, and quality of life were not addressed in most studies and should also serve as areas for future research. The timing of S/E assessment might influence detection of toxicity. Coadministration of drugs as dopamine receptor blockers may also influence response; 1 study demonstrated antagonistic activities of MP effects and haloperidol in those with ADHD. 26 Our data had several disadvantages, separately the studies were not powered to detect side effects, and it was not controlled for placebo effects. However, the participants were representative of our palliative care cancer population; data was collected using a standardized collection sheet and according to a uniform schedule. Pooled data allowed for a larger sample size to evaluate new symptoms that might reasonably be attributed to MP. Based on our open-label studies, 96% responded to MP treatment for the major indication. Positive treatment effects were achieved within 3 days using a low dose (10 mg/day) in 70%. In addition, other secondary symptoms like anorexia were significantly reduced; this might be secondary to improvement in depression, fatigue, or an independent therapeutic effect. This suggests additional multisymptom benefits to MP that needs to be confirmed in future studies. This analysis has several clinical implications. Methylphenidate appears to be a safe, effective, medication (and is relatively inexpensive). It apparently palliates multiple symptoms, and may do so simultaneously. It is relatively ideal for those with an expected short survival due to its rapid onset of action (compared to other agents) for depression. As it is cheap, MP will benefit those in hospice capitated reimbursement programs. Research should further clarify the benefits in cancer-related fatigue, MP effectiveness compared to other antidepressants, the place of MP in opioid related sedation, the influence on quality of life, the beneficial effects on performance status, and hospital length of stay. Dose, timing, and formulation (sustained release versus normal release) need to be studied further. A randomized trial comparing MP to other antidepressants in advanced cancer would better define MP clinical benefits in advanced cancer.
Summary
Methylphenidate is relatively well tolerated in advanced cancer. Withdrawal due to likely adverse events occurred in 11%. It had a quick onset of action and was effective for both depression and fatigue. Methylphenidate is safe to use in advanced cancer and can palliate multiple common symptoms. Future research should examine dose, timing, and preparation variables. A randomized trial comparing MP with standard antidepressants in depression or placebo with fatigue would better define its benefits in advanced cancer. 
